Xiang Li

Xiang Li


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2022 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
JLJingru Lu
Jingru Lu
XLXiaoshuang Liu
Xiaoshuang Liu
SJSong Jiang
Song Jiang
SKShuyan Kan
Shuyan Kan
YAYu An
Yu An
GXGuotong Xie
Guotong Xie
Context The associations of obesity and diabetic nephropathy (DN) in type 2 diabetes are inconsistent in observational studies, and causality remains unclear. Objective To explore the causal effect of body mass index (BMI) on DN, estimated glomerular filtration rate (eGFR), and proteinuria in type 2 diabetes by a 2-sample Mendelian randomization (MR) analysis. Methods A total of 56 genetic variants were selected as instrumental variables for BMI in 158 284 participants from BioBank Japan, and their effects on DN risk, eGFR, and proteinuria were estimated in 3972 individuals with type 2 diabetes. Then, sex-stratified MR analysis was performed between BMI and DN. We selected generalized summary MR analysis as the primary method and 6 other robust methods to test MR assumptions. Results One SD increase in BMI was causally associated with higher DN risk [odds ratio (OR) 3.76, 95% CI 1.88-7.53, P < 0.001] and lower eGFR level (OR 0.71, 95% CI 0.59-0.86, P < 0.001). However, BMI was not causally associated with proteinuria (P = 0.22). Sex-stratified analyses indicated the causal effect of BMI on DN was stronger in women (OR 14.81, 95% CI 2.67-82.05, P = 0.002) than in men (OR 3.48, 95% CI 1.18-10.27, P = 0.02). Sensitivity analyses did not show evidence for violation of the MR assumptions. Conclusions Genetic evidence showed that higher BMI levels were causally associated with increased risk of DN and decreased eGFR levels. Moreover, the increase in BMI level had a greater impact on DN risk in women.

3 December 2019 in Kidney Diseases
Verified
Journal Article
Open access
PDF file
GXGuotong Xie
Guotong Xie
TCTiange Chen
Tiange Chen
YLYingxue Li
Yingxue Li
TCTingyu Chen
Tingyu Chen
XLXiang Li
Xiang Li
ZLZhihong Liu
Zhihong Liu
Background: Artificial intelligence (AI) now plays a critical role in almost every area of our daily lives and academic disciplines due to the growth of computing power, advances in methods and techniques, and the explosion of the amount of data; medicine is not an exception. Rather than replacing clinicians, AI is augmenting the intelligence of clinicians in diagnosis, prognosis, and treatment decisions. Summary: Kidney disease is a substantial medical and public health burden globally, with both acute kidney injury and chronic kidney disease bringing about high morbidity and mortality as well as a huge economic burden. Even though the existing research and applied works have made certain contributions to more accurate prediction and better understanding of histologic pathology, there is a lot more work to be done and problems to solve. Key Messages: AI applications of diagnostics and prognostics for high-prevalence and high-morbidity types of nephropathy in medical-resource-inadequate areas need special attention; high-volume and high-quality data need to be collected and prepared; a consensus on ethics and safety in the use of AI technologies needs to be built.

30 July 2024 in Journal of Medical Internet Research
Verified
Journal Article
Open access
JYJingang Yang
Jingang Yang
YLYingxue Li
Yingxue Li
XLXiang Li
Xiang Li
STShuiying Tao
Shuiying Tao
YZYuan Zhang
Yuan Zhang
YYYuejin Yang
Yuejin Yang
Background: Machine learning (ML) risk prediction models, although much more accurate than traditional statistical methods, are inconvenient to use in clinical practice due to their nontransparency and requirement of a large number of input variables. Objective: We aimed to develop a precise, explainable, and flexible ML model to predict the risk of in-hospital mortality in patients with ST-segment elevation myocardial infarction (STEMI). Methods: This study recruited 18,744 patients enrolled in the 2013 China Acute Myocardial Infarction (CAMI) registry and 12,018 patients from the China Patient-Centered Evaluative Assessment of Cardiac Events (PEACE)-Retrospective Acute Myocardial Infarction Study. The Extreme Gradient Boosting (XGBoost) model was derived from 9616 patients in the CAMI registry (2014, 89 variables) with 5-fold cross-validation and validated on both the 9125 patients in the CAMI registry (89 variables) and the independent China PEACE cohort (10 variables). The Shapley Additive Explanations (SHAP) approach was employed to interpret the complex relationships embedded in the proposed model. Results: In the XGBoost model for predicting all-cause in-hospital mortality, the variables with the top 8 most important scores were age, left ventricular ejection fraction, Killip class, heart rate, creatinine, blood glucose, white blood cell count, and use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs). The area under the curve (AUC) on the CAMI validation set was 0.896 (95% CI 0.884-0.909), significantly higher than the previous models. The AUC for the Global Registry of Acute Coronary Events (GRACE) model was 0.809 (95% CI 0.790-0.828), and for the TIMI model, it was 0.782 (95% CI 0.763-0.800). Despite the China PEACE validation set only having 10 available variables, the AUC reached 0.840 (0.829-0.852), showing a substantial improvement to the GRACE (0.762, 95% CI 0.748-0.776) and TIMI (0.789, 95% CI 0.776-0.803) scores. Several novel and nonlinear relationships were discovered between patients’ characteristics and in-hospital mortality, including a U-shape pattern of high-density lipoprotein cholesterol (HDL-C). Conclusions: The proposed ML risk prediction model was highly accurate in predicting in-hospital mortality. Its flexible and explainable characteristics make the model convenient to use in clinical practice and could help guide patient management. Trial Registration: ClinicalTrials.gov NCT01874691; https://clinicaltrials.gov/study/NCT01874691

4 June 2020 in Journal of Healthcare Informatics Research
Verified
Journal Article
Closed access
PDF file
XXXiao Xu
Xiao Xu
XLXiaoshuang Liu
Xiaoshuang Liu
YKYanni Kang
Yanni Kang
XXXian Xu
Xian Xu
JWJunmei Wang
Junmei Wang
GXGuotong Xie
Guotong Xie

6 January 2021 in Journal of Healthcare Informatics Research
Verified
Journal Article
Closed access
PDF file
YLYingxue Li
Yingxue Li
WJWenxiao Jia
Wenxiao Jia
JWJunmei Wang
Junmei Wang
JGJianying Guo
Jianying Guo
QLQin Liu
Qin Liu
FWFei Wang
Fei Wang

14 March 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
SHSiwan Huang
Siwan Huang
YCYinghua Chen
Yinghua Chen
YSYanan Song
Yanan Song
KWKaiyuan Wu
Kaiyuan Wu
TCTiange Chen
Tiange Chen
ZLZhihong Liu
Zhihong Liu
Objectives To develop an interpretable deep learning model of lupus nephritis (LN) relapse prediction based on dynamic multivariable time-series data. Design A single-centre, retrospective cohort study in China. Setting A Chinese central tertiary hospital. Participants The cohort study consisted of 1694 LN patients who had been registered in the Nanjing Glomerulonephritis Registry at the National Clinical Research Center of Kidney Diseases, Jinling Hospital from January 1985 to December 2010. Methods We developed a deep learning algorithm to predict LN relapse that consists of 59 features, including demographic, clinical, immunological, pathological and therapeutic characteristics that were collected for baseline analysis. A total of 32 227 data points were collected by the sliding window method and randomly divided into training (80%), validation (10%) and testing sets (10%). We developed a deep learning algorithm-based interpretable multivariable long short-term memory model for LN relapse risk prediction considering censored time-series data based on a cohort of 1694 LN patients. A mixture attention mechanism was deployed to capture variable interactions at different time points for estimating the temporal importance of the variables. Model performance was assessed according to C-index (concordance index). Results The median follow-up time since remission was 4.1 (IQR, 1.7–6.7) years. The interpretable deep learning model based on dynamic multivariable time-series data achieved the best performance, with a C-index of 0.897, among models using only variables at the point of remission or time-variant variables. The importance of urinary protein, serum albumin and serum C3 showed time dependency in the model, that is, their contributions to the risk prediction increased over time. Conclusions Deep learning algorithms can effectively learn through time-series data to develop a predictive model for LN relapse. The model provides accurate predictions of LN relapse for different renal disease stages, which could be used in clinical practice to guide physicians on the management of LN patients.